Congress
$1,001–$15,000
Traded Aug 27 · disclosed 16 days laterSits on House Energy and Commerce
4 different filers disclosed JNJ within 90 days.
Ask OQRO reads the filings behind this page and answers in plain words, with a link to each source.
Ask OQRO is part of OQRO Pro. Everything else on OQRO is free.
Only to see which pages are hard to use, so we can fix them. Nothing is used for ads, and what you type stays hidden (Microsoft Clarity, PostHog). Privacy Policy
Traded Aug 13, 2026 · Filed Aug 14, 2026
The CEO of Johnson & Johnson sold $5.5M of Johnson & Johnson shares. The filing does not indicate a pre-arranged trading plan.
Written from the filing's own figures. OQRO describes what was reported and never tells you what to buy or sell.
open market sale
Code S — open-market or private sale
~$5,495,712
Shares × reported transaction price
29 days after results of Jul 15, 2026, 61 days before results of Oct 13, 2026
Results dates are the company's own 8-K (Item 2.02). Many companies only let insiders trade in a window after results
Closed at $262.08 on Aug 13, 2026, within 2% of its 52-week high, after a 3% rise over the previous 30 trading days
52-week range $174.16 (Sep 18, 2025) to $267.24 (Jul 7, 2026), 94% of the way up, from 251 adjusted closes. 30 trading days earlier: $253.98 on Jul 1, 2026. Describes the past only, not a forecast
RSI 58, 14% above its 200-day average, 5% above its 50-day average, 2% below the 52-week high, 20-day volatility 21% a year, against the S&P 500: +3 points over 1 month, +9 points over 3 months, −4 points over 6 months
From the adjusted closes up to Aug 13, 2026. RSI: Wilder's 14-day relative strength index (0 to 100). Averages: the last 50 and 200 closes. Volatility: standard deviation of the last 20 daily returns, annualised. S&P 500: the stock's move minus SPY's between the same dates (21, 63 and 126 trading days). Describes the past only, not a forecast
None found in footnotes
Only flagged when a footnote says so; never inferred
FDA approved Imaavy on Aug 24, 2026, 11 days after this trade.
New use approved (efficacy supplement). Active ingredient: Nipocalimab-Aahu. From openFDA. Dates only; no link between the two is implied
| After | Stock | S&P 500 | Difference |
|---|---|---|---|
| 7 days | +4.1% | −1.2% | +5.3% |
| 30 days | +1.9% | −2.4% | +4.3% |
| 90 days | +7.7% | −4.2% | +11.9% |
Past results only. Not a forecast.
Congress
Traded Aug 27 · disclosed 16 days laterSits on House Energy and Commerce
4 different filers disclosed JNJ within 90 days.
Insider filing
Traded Sep 8 · filed 3 days later
Compensation award — excluded from discretionary-purchase analysis.
Insider filing
Traded Sep 8 · filed 3 days later
Compensation award — excluded from discretionary-purchase analysis.
Every dated public record OQRO holds about the company from 60 days before to 120 days after, oldest first. It shows what was going on; none of it is a stated reason for the trade.